Homozygous NMNAT2 mutation in sisters with polyneuropathy and erythromelalgia - PubMed

Affiliations

• PMID: 31132363
• DOI: 10.1016/j.expneurol.2019.112958

Case Reports

Homozygous NMNAT2 mutation in sisters with polyneuropathy and erythromelalgia

Peter Huppke et al. Exp Neurol. 2019 Oct.

Abstract

We identified a homozygous missense mutation in the gene encoding NAD synthesizing enzyme NMNAT2 in two siblings with childhood onset polyneuropathy with erythromelalgia. No additional homozygotes for this rare allele, which leads to amino acid substitution T94M, were present among the unaffected relatives tested or in the 60,000 exomes of the ExAC database. For axons to survive, axonal NMNAT2 activity has to be maintained above a threshold level but the T94M mutation confers a partial loss of function both in the ability of NMNAT2 to support axon survival and in its enzymatic properties. Electrophysiological tests and histological analysis of sural nerve biopsies in the patients were consistent with loss of distal sensory and motor axons. Thus, it is likely that NMNAT2 mutation causes this pain and axon loss phenotype making this the first disorder associated with mutation of a key regulator of Wallerian-like axon degeneration in humans. This supports indications from numerous animal studies that the Wallerian degeneration pathway is important in human disease and raises important questions about which other human phenotypes could be linked to this gene.

Keywords: Erythromelalgia; NAD; NMNAT2; Polyneuropathy; Wallerian degeneration.

Similar articles

• Severe biallelic loss-of-function mutations in nicotinamide mononucleotide adenylyltransferase 2 (NMNAT2) in two fetuses with fetal akinesia deformation sequence.

  Lukacs M, Gilley J, Zhu Y, Orsomando G, Angeletti C, Liu J, Yang X, Park J, Hopkin RJ, Coleman MP, Zhai RG, Stottmann RW. Lukacs M, et al. Exp Neurol. 2019 Oct;320:112961. doi: 10.1016/j.expneurol.2019.112961. Epub 2019 May 25. Exp Neurol. 2019. PMID: 31136762 Free PMC article.

• NMN Deamidase Delays Wallerian Degeneration and Rescues Axonal Defects Caused by NMNAT2 Deficiency In Vivo.

  Di Stefano M, Loreto A, Orsomando G, Mori V, Zamporlini F, Hulse RP, Webster J, Donaldson LF, Gering M, Raffaelli N, Coleman MP, Gilley J, Conforti L. Di Stefano M, et al. Curr Biol. 2017 Mar 20;27(6):784-794. doi: 10.1016/j.cub.2017.01.070. Epub 2017 Mar 2. Curr Biol. 2017. PMID: 28262487

• Mitochondrial impairment activates the Wallerian pathway through depletion of NMNAT2 leading to SARM1-dependent axon degeneration.

  Loreto A, Hill CS, Hewitt VL, Orsomando G, Angeletti C, Gilley J, Lucci C, Sanchez-Martinez A, Whitworth AJ, Conforti L, Dajas-Bailador F, Coleman MP. Loreto A, et al. Neurobiol Dis. 2020 Feb;134:104678. doi: 10.1016/j.nbd.2019.104678. Epub 2019 Nov 15. Neurobiol Dis. 2020. PMID: 31740269 Free PMC article.

• Wallerian degeneration: an emerging axon death pathway linking injury and disease.

  Conforti L, Gilley J, Coleman MP. Conforti L, et al. Nat Rev Neurosci. 2014 Jun;15(6):394-409. doi: 10.1038/nrn3680. Nat Rev Neurosci. 2014. PMID: 24840802 Review.

• NMNAT2: An important metabolic enzyme affecting the disease progression.

  Li W, Gao M, Hu C, Chen X, Zhou Y. Li W, et al. Biomed Pharmacother. 2023 Feb;158:114143. doi: 10.1016/j.biopha.2022.114143. Epub 2022 Dec 16. Biomed Pharmacother. 2023. PMID: 36528916 Review.

Cited by

• NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual function.

  Fang F, Zhuang P, Feng X, Liu P, Liu D, Huang H, Li L, Chen W, Liu L, Sun Y, Jiang H, Ye J, Hu Y. Fang F, et al. Mol Ther. 2022 Apr 6;30(4):1421-1431. doi: 10.1016/j.ymthe.2022.01.035. Epub 2022 Jan 31. Mol Ther. 2022. PMID: 35114390 Free PMC article.

• Natural variants of human SARM1 cause both intrinsic and dominant loss-of-function influencing axon survival.

  Ademi M, Yang X, Coleman MP, Gilley J. Ademi M, et al. Sci Rep. 2022 Aug 16;12(1):13846. doi: 10.1038/s41598-022-18052-8. Sci Rep. 2022. PMID: 35974060 Free PMC article.

• Lessons from Injury: How Nerve Injury Studies Reveal Basic Biological Mechanisms and Therapeutic Opportunities for Peripheral Nerve Diseases.

  Arthur-Farraj P, Coleman MP. Arthur-Farraj P, et al. Neurotherapeutics. 2021 Oct;18(4):2200-2221. doi: 10.1007/s13311-021-01125-3. Epub 2021 Sep 30. Neurotherapeutics. 2021. PMID: 34595734 Free PMC article. Review.

• Location, Location, Location: Compartmentalization of NAD⁺ Synthesis and Functions in Mammalian Cells.

  Cambronne XA, Kraus WL. Cambronne XA, et al. Trends Biochem Sci. 2020 Oct;45(10):858-873. doi: 10.1016/j.tibs.2020.05.010. Epub 2020 Jun 25. Trends Biochem Sci. 2020. PMID: 32595066 Free PMC article. Review.

• Chronically Low NMNAT2 Expression Causes Sub-lethal SARM1 Activation and Altered Response to Nicotinamide Riboside in Axons.

  Antoniou C, Loreto A, Gilley J, Merlini E, Orsomando G, Coleman MP. Antoniou C, et al. Mol Neurobiol. 2025 Mar;62(3):3903-3917. doi: 10.1007/s12035-024-04480-2. Epub 2024 Oct 1. Mol Neurobiol. 2025. PMID: 39352636 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Molecular Biology Databases

  • GlyGen glycoinformatics resource